Anthrax is an infection caused by the bacterium Bacillus anthracis. It can occur in four forms: skin, lungs, intestinal, and injection. Symptoms begin between one day and two months after the infection is contracted. The skin form presents with a small blister with surrounding swelling that often turns into a painless ulcer with a black center. The inhalation form presents with fever, chest pain, and shortness of breath. The intestinal form presents with diarrhea which may contain blood, abdominal pains, and nausea and vomiting. The injection form presents with fever and an abscess at the site of drug injection.
|A skin lesion caused by anthrax; the characteristic black eschar|
|Symptoms||Skin form: small blister with surrounding swelling|
Inhalational form: fever, chest pain, shortness of breath
Intestinal form: nausea, vomiting, diarrhea, abdominal pain
Injection form: fever, abscess
|Usual onset||1 day to 2 months post contact|
|Risk factors||Working with animals, travelers, postal workers, military personnel|
|Diagnostic method||Based on antibodies or toxin in the blood, microbial culture|
|Prevention||Anthrax vaccination, antibiotics|
|Prognosis||20–80% die without treatment|
|Frequency||>2,000 cases per year|
Anthrax is spread by contact with the bacterium's spores, which often appear in infectious animal products. Contact is by breathing, eating, or through an area of broken skin. It does not typically spread directly between people. Risk factors include people who work with animals or animal products, travelers, postal workers, and military personnel. Diagnosis can be confirmed based on finding antibodies or the toxin in the blood or by culture of a sample from the infected site.
Anthrax vaccination is recommended for people who are at high risk of infection. Immunizing animals against anthrax is recommended in areas where previous infections have occurred. Two months of antibiotics such as ciprofloxacin, levofloxacin, and doxycycline after exposure can also prevent infection. If infection occurs treatment is with antibiotics and possibly antitoxin. The type and number of antibiotics used depends on the type of infection. Antitoxin is recommended for those with widespread infection.
Although a rare disease, human anthrax, when it does occur, is most common in Africa and central and southern Asia. It also occurs more regularly in Southern Europe than elsewhere on the continent, and is uncommon in Northern Europe and North America. Globally, at least 2,000 cases occur a year with about two cases a year in the United States. Skin infections represent more than 95% of cases. Without treatment, the risk of death from skin anthrax is 24%. For intestinal infection, the risk of death is 25 to 75%, while respiratory anthrax has a mortality of 50 to 80%, even with treatment. Until the 20th century, anthrax infections killed hundreds of thousands of people and animals each year. Anthrax has been developed as a weapon by a number of countries. In plant-eating animals, infection occurs when they eat or breathe in the spores while grazing. Carnivores may become infected by eating infected animals.
Signs and symptoms
Cutaneous anthrax, also known as hide-porter's disease, is when anthrax occurs on the skin. It is the most common form (>90% of anthrax cases). It is also the least dangerous form (low mortality with treatment, 20% mortality without). Cutaneous anthrax presents as a boil-like skin lesion that eventually forms an ulcer with a black center (eschar). The black eschar often shows up as a large, painless, necrotic ulcer (beginning as an irritating and itchy skin lesion or blister that is dark and usually concentrated as a black dot, somewhat resembling bread mold) at the site of infection. In general, cutaneous infections form within the site of spore penetration between two and five days after exposure. Unlike bruises or most other lesions, cutaneous anthrax infections normally do not cause pain. Nearby lymph nodes may become infected, reddened, swollen, and painful. A scab forms over the lesion soon, and falls off in a few weeks. Complete recovery may take longer. Cutaneous anthrax is typically caused when B. anthracis spores enter through cuts on the skin. This form is found most commonly when humans handle infected animals and/or animal products.
Cutaneous anthrax is rarely fatal if treated, because the infection area is limited to the skin, preventing the lethal factor, edema factor, and protective antigen from entering and destroying a vital organ. Without treatment, about 20% of cutaneous skin infection cases progress to toxemia and death.
Respiratory infection in humans is relatively rare and presents as two stages. It infects the lymph nodes in the chest first, rather than the lungs themselves, a condition called hemorrhagic mediastinitis, causing bloody fluid to accumulate in the chest cavity, therefore causing shortness of breath. The first stage causes cold and flu-like symptoms. Symptoms include fever, shortness of breath, cough, fatigue, and chills. This can last hours to days. Often, many fatalities from inhalational anthrax are when the first stage is mistaken for the cold or flu and the victim does not seek treatment until the second stage, which is 90% fatal. The second (pneumonia) stage occurs when the infection spreads from the lymph nodes to the lungs. Symptoms of the second stage develop suddenly after hours or days of the first stage. Symptoms include high fever, extreme shortness of breath, shock, and rapid death within 48 hours in fatal cases. Historical mortality rates were over 85%, but when treated early (seen in the 2001 anthrax attacks), observed case fatality rate dropped to 45%. Distinguishing pulmonary anthrax from more common causes of respiratory illness is essential to avoiding delays in diagnosis and thereby improving outcomes. An algorithm for this purpose has been developed.
Gastrointestinal (GI) infection is most often caused by consuming anthrax-infected meat and is characterized by diarrhea, potentially with blood, abdominal pains, acute inflammation of the intestinal tract, and loss of appetite. Occasional vomiting of blood can occur. Lesions have been found in the intestines and in the mouth and throat. After the bacterium invades the gastrointestinal system, it spreads to the bloodstream and throughout the body, while continuing to make toxins. GI infections can be treated, but usually result in fatality rates of 25% to 60%, depending upon how soon treatment commences. This form of anthrax is the rarest.
Bacillus anthracis is a rod-shaped, Gram-positive, facultative anaerobic bacterium about 1 by 9 μm in size. It was shown to cause disease by Robert Koch in 1876 when he took a blood sample from an infected cow, isolated the bacteria, and put them into a mouse. The bacterium normally rests in spore form in the soil, and can survive for decades in this state. Herbivores are often infected whilst grazing, especially when eating rough, irritant, or spiky vegetation; the vegetation has been hypothesized to cause wounds within the GI tract, permitting entry of the bacterial spores into the tissues, though this has not been proven. Once ingested or placed in an open wound, the bacteria begin multiplying inside the animal or human and typically kill the host within a few days or weeks. The spores germinate at the site of entry into the tissues and then spread by the circulation to the lymphatics, where the bacteria multiply.
The production of two powerful exotoxins and lethal toxin by the bacteria causes death. Veterinarians can often tell a possible anthrax-induced death by its sudden occurrence, and by the dark, nonclotting blood that oozes from the body orifices. Most anthrax bacteria inside the body after death are outcompeted and destroyed by anaerobic bacteria within minutes to hours post mortem. However, anthrax vegetative bacteria that escape the body via oozing blood or through the opening of the carcass may form hardy spores. These vegetative bacteria are not contagious. One spore forms per one vegetative bacterium. The triggers for spore formation are not yet known, though oxygen tension and lack of nutrients may play roles. Once formed, these spores are very hard to eradicate.
The infection of herbivores (and occasionally humans) by the inhalational route normally proceeds as: Once the spores are inhaled, they are transported through the air passages into the tiny air sacs (alveoli) in the lungs. The spores are then picked up by scavenger cells (macrophages) in the lungs and are transported through small vessels (lymphatics) to the lymph nodes in the central chest cavity (mediastinum). Damage caused by the anthrax spores and bacilli to the central chest cavity can cause chest pain and difficulty in breathing. Once in the lymph nodes, the spores germinate into active bacilli that multiply and eventually burst the macrophages, releasing many more bacilli into the bloodstream to be transferred to the entire body. Once in the blood stream, these bacilli release three proteins named lethal factor, edema factor, and protective antigen. The three are not toxic by themselves, but their combination is incredibly lethal to humans. Protective antigen combines with these other two factors to form lethal toxin and edema toxin, respectively. These toxins are the primary agents of tissue destruction, bleeding, and death of the host. If antibiotics are administered too late, even if the antibiotics eradicate the bacteria, some hosts still die of toxemia because the toxins produced by the bacilli remain in their systems at lethal dose levels.
- Bacillus anthracis
The spores of anthrax are able to survive in harsh conditions for decades or even centuries. Such spores can be found on all continents, including Antarctica. Disturbed grave sites of infected animals have been known to cause infection after 70 years.
Occupational exposure to infected animals or their products (such as skin, wool, and meat) is the usual pathway of exposure for humans. Workers who are exposed to dead animals and animal products are at the highest risk, especially in countries where anthrax is more common. Anthrax in livestock grazing on open range where they mix with wild animals still occasionally occurs in the United States and elsewhere. Many workers who deal with wool and animal hides are routinely exposed to low levels of anthrax spores, but most exposure levels are not sufficient to develop anthrax infections. A lethal infection is reported to result from inhalation of about 10,000–20,000 spores, though this dose varies among host species. Little documented evidence is available to verify the exact or average number of spores needed for infection.
Historically, inhalational anthrax was called woolsorters' disease because it was an occupational hazard for people who sorted wool. Today, this form of infection is extremely rare in advanced nations, as almost no infected animals remain.
Mode of infection
Anthrax can enter the human body through the intestines (ingestion), lungs (inhalation), or skin (cutaneous) and causes distinct clinical symptoms based on its site of entry. In general, an infected human is quarantined. However, anthrax does not usually spread from an infected human to an uninfected human. If the disease is fatal to the person's body, though, its mass of anthrax bacilli becomes a potential source of infection to others and special precautions should be used to prevent further contamination. Inhalational anthrax, if left untreated until obvious symptoms occur, is usually fatal.
Anthrax can be contracted in laboratory accidents or by handling infected animals, their wool, or their hides. It has also been used in biological warfare agents and by terrorists to intentionally infect as exemplified by the 2001 anthrax attacks.
The lethality of the anthrax disease is due to the bacterium's two principal virulence factors: the poly-D-glutamic acid capsule, which protects the bacterium from phagocytosis by host neutrophils, and the tripartite protein toxin, called anthrax toxin. Anthrax toxin is a mixture of three protein components: protective antigen (PA), edema factor (EF), and lethal factor (LF). PA plus LF produces lethal toxin, and PA plus EF produces edema toxin. These toxins cause death and tissue swelling (edema), respectively.
To enter the cells, the edema and lethal factors use another protein produced by B. anthracis called protective antigen, which binds to two surface receptors on the host cell. A cell protease then cleaves PA into two fragments: PA20 and PA63. PA20 dissociates into the extracellular medium, playing no further role in the toxic cycle. PA63 then oligomerizes with six other PA63 fragments forming a heptameric ring-shaped structure named a prepore. Once in this shape, the complex can competitively bind up to three EFs or LFs, forming a resistant complex. Receptor-mediated endocytosis occurs next, providing the newly formed toxic complex access to the interior of the host cell. The acidified environment within the endosome triggers the heptamer to release the LF and/or EF into the cytosol. It is unknown how exactly the complex results in the death of the cell.
Edema factor is a calmodulin-dependent adenylate cyclase. Adenylate cyclase catalyzes the conversion of ATP into cyclic AMP (cAMP) and pyrophosphate. The complexation of adenylate cyclase with calmodulin removes calmodulin from stimulating calcium-triggered signaling, thus inhibiting the immune response. To be specific, LF inactivates neutrophils (a type of phagocytic cell) by the process just described so they cannot phagocytose bacteria. Throughout history, lethal factor was presumed to cause macrophages to make TNF-alpha and interleukin 1, beta (IL1B). TNF-alpha is a cytokine whose primary role is to regulate immune cells, as well as to induce inflammation and apoptosis or programmed cell death. Interleukin 1, beta is another cytokine that also regulates inflammation and apoptosis. The overproduction of TNF-alpha and IL1B ultimately leads to septic shock and death. However, recent evidence indicates anthrax also targets endothelial cells that line serous cavities such as the pericardial cavity, pleural cavity, and peritoneal cavity, lymph vessels, and blood vessels, causing vascular leakage of fluid and cells, and ultimately hypovolemic shock and septic shock.
Various techniques may be used for the direct identification of B. anthracis in clinical material. Firstly, specimens may be Gram stained. Bacillus spp. are quite large in size (3 to 4 μm long), they may grow in long chains, and they stain Gram-positive. To confirm the organism is B. anthracis, rapid diagnostic techniques such as polymerase chain reaction-based assays and immunofluorescence microscopy may be used.
All Bacillus species grow well on 5% sheep blood agar and other routine culture media. Polymyxin-lysozyme-EDTA-thallous acetate can be used to isolate B. anthracis from contaminated specimens, and bicarbonate agar is used as an identification method to induce capsule formation. Bacillus spp. usually grow within 24 hours of incubation at 35 °C, in ambient air (room temperature) or in 5% CO2. If bicarbonate agar is used for identification, then the medium must be incubated in 5% CO2. B. anthracis colonies are medium-large, gray, flat, and irregular with swirling projections, often referred to as having a "medusa head" appearance, and are not hemolytic on 5% sheep blood agar. The bacteria are not motile, susceptible to penicillin, and produce a wide zone of lecithinase on egg yolk agar. Confirmatory testing to identify B. anthracis includes gamma bacteriophage testing, indirect hemagglutination, and enzyme-linked immunosorbent assay to detect antibodies. The best confirmatory precipitation test for anthrax is the Ascoli test.
If a person is suspected as having died from anthrax, precautions should be taken to avoid skin contact with the potentially contaminated body and fluids exuded through natural body openings. The body should be put in strict quarantine. A blood sample should then be collected and sealed in a container and analyzed in an approved laboratory to ascertain if anthrax is the cause of death. Then, the body should be incinerated. Microscopic visualization of the encapsulated bacilli, usually in very large numbers, in a blood smear stained with polychrome methylene blue (McFadyean stain) is fully diagnostic, though culture of the organism is still the gold standard for diagnosis. Full isolation of the body is important to prevent possible contamination of others. Protective, impermeable clothing and equipment such as rubber gloves, rubber apron, and rubber boots with no perforations should be used when handling the body. No skin, especially if it has any wounds or scratches, should be exposed. Disposable personal protective equipment is preferable, but if not available, decontamination can be achieved by autoclaving. Disposable personal protective equipment and filters should be autoclaved, and/or burned and buried. Anyone working with anthrax in a suspected or confirmed person should wear respiratory equipment capable of filtering particles of their size or smaller. The US National Institute for Occupational Safety and Health – and Mine Safety and Health Administration-approved high-efficiency respirator, such as a half-face disposable respirator with a high-efficiency particulate air filter, is recommended. All possibly contaminated bedding or clothing should be isolated in double plastic bags and treated as possible biohazard waste. The body of an infected person should be sealed in an airtight body bag. Dead people who are opened and not burned provide an ideal source of anthrax spores. Cremating people is the preferred way of handling body disposal. No embalming or autopsy should be attempted without a fully equipped biohazard laboratory and trained, knowledgeable personnel.
Vaccines against anthrax for use in livestock and humans have had a prominent place in the history of medicine. The French scientist Louis Pasteur developed the first effective vaccine in 1881. Human anthrax vaccines were developed by the Soviet Union in the late 1930s and in the US and UK in the 1950s. The current FDA-approved US vaccine was formulated in the 1960s.
Currently administered human anthrax vaccines include acellular (United States) and live vaccine (Russia) varieties. All currently used anthrax vaccines show considerable local and general reactogenicity (erythema, induration, soreness, fever) and serious adverse reactions occur in about 1% of recipients. The American product, BioThrax, is licensed by the FDA and was formerly administered in a six-dose primary series at 0, 2, 4 weeks and 6, 12, 18 months, with annual boosters to maintain immunity. In 2008, the FDA approved omitting the week-2 dose, resulting in the currently recommended five-dose series. New second-generation vaccines currently being researched include recombinant live vaccines and recombinant subunit vaccines. In the 20th century the use of a modern product (BioThrax) to protect American troops against the use of anthrax in biological warfare was controversial.
Preventive antibiotics are recommended in those who have been exposed. Early detection of sources of anthrax infection can allow preventive measures to be taken. In response to the anthrax attacks of October 2001, the United States Postal Service (USPS) installed biodetection systems (BDSs) in their large-scale mail processing facilities. BDS response plans were formulated by the USPS in conjunction with local responders including fire, police, hospitals, and public health. Employees of these facilities have been educated about anthrax, response actions, and prophylactic medication. Because of the time delay inherent in getting final verification that anthrax has been used, prophylactic antibiotic treatment of possibly exposed personnel must be started as soon as possible.
Anthrax cannot be spread directly from person to person, but a person's clothing and body may be contaminated with anthrax spores. Effective decontamination of people can be accomplished by a thorough wash-down with antimicrobial soap and water. Waste water should be treated with bleach or another antimicrobial agent. Effective decontamination of articles can be accomplished by boiling them in water for 30 minutes or longer. Chlorine bleach is ineffective in destroying spores and vegetative cells on surfaces, though formaldehyde is effective. Burning clothing is very effective in destroying spores. After decontamination, there is no need to immunize, treat, or isolate contacts of persons ill with anthrax unless they were also exposed to the same source of infection.
Early antibiotic treatment of anthrax is essential; delay significantly lessens chances for survival.
Treatment for anthrax infection and other bacterial infections includes large doses of intravenous and oral antibiotics, such as fluoroquinolones (ciprofloxacin), doxycycline, erythromycin, vancomycin, or penicillin. FDA-approved agents include ciprofloxacin, doxycycline, and penicillin.
In possible cases of pulmonary anthrax, early antibiotic prophylaxis treatment is crucial to prevent possible death.
In recent years, many attempts have been made to develop new drugs against anthrax, but existing drugs are effective if treatment is started soon enough.
In May 2009, Human Genome Sciences submitted a biologic license application (BLA, permission to market) for its new drug, raxibacumab (brand name ABthrax) intended for emergency treatment of inhaled anthrax. On 14 December 2012, the US Food and Drug Administration approved raxibacumab injection to treat inhalational anthrax. Raxibacumab is a monoclonal antibody that neutralizes toxins produced by B. anthracis. On March, 2016, FDA approved a second anthrax treatment using a monoclonal antibody which neutralizes the toxins produced by B. anthracis. Obiltoxaximab is approved to treat inhalational anthrax in conjunction with appropriate antibacterial drugs, and for prevention when alternative therapies are not available or appropriate.
The last fatal case of natural inhalational anthrax in the United States occurred in California in 1976, when a home weaver died after working with infected wool imported from Pakistan. To minimize the chance of spreading the disease, the deceased was transported to UCLA in a sealed plastic body bag within a sealed metal container for autopsy.
Gastrointestinal anthrax is exceedingly rare in the United States, with only two cases on record. The first case was reported in 1942, according to the Centers for Disease Control and Prevention. During December 2009, the New Hampshire Department of Health and Human Services confirmed a case of gastrointestinal anthrax in an adult female.
The CDC investigated the source of the December 2009 infection and the possibility that it was contracted from an African drum recently used by the woman taking part in a drum circle. The woman apparently inhaled anthrax, in spore form, from the hide of the drum. She became critically ill, but with gastrointestinal anthrax rather than inhaled anthrax, which made her unique in American medical history. The building where the infection took place was cleaned and reopened to the public and the woman recovered. The New Hampshire state epidemiologist, Jodie Dionne-Odom, stated "It is a mystery. We really don't know why it happened."
In November 2008, a drum maker in the United Kingdom who worked with untreated animal skins died from anthrax. In December 2009, an outbreak of anthrax occurred amongst heroin addicts in the Glasgow and Stirling areas of Scotland, resulting in 14 deaths. The source of the anthrax is believed to be dilution of the heroin with bone meal in Afghanistan.
The English name comes from anthrax (ἄνθραξ), the Greek word for coal, possibly having Egyptian etymology, because of the characteristic black skin lesions developed by victims with a cutaneous anthrax infection. The central, black eschar, surrounded by vivid red skin has long been recognised as typical of the disease. The first recorded use of the word "anthrax" in English is in a 1398 translation of Bartholomaeus Anglicus' work De proprietatibus rerum (On the Properties of Things, 1240).
Anthrax has been known by a wide variety of names, indicating its symptoms, location and groups considered most vulnerable to infection. These include Siberian plague, Cumberland disease, charbon, splenic fever, malignant edema, woolsorter's disease, and even la maladie de Bradford.
Robert Koch, a German physician and scientist, first identified the bacterium that caused the anthrax disease in 1875 in Wolsztyn (now part of Poland). His pioneering work in the late 19th century was one of the first demonstrations that diseases could be caused by microbes. In a groundbreaking series of experiments, he uncovered the lifecycle and means of transmission of anthrax. His experiments not only helped create an understanding of anthrax, but also helped elucidate the role of microbes in causing illness at a time when debates still took place over spontaneous generation versus cell theory. Koch went on to study the mechanisms of other diseases and won the 1905 Nobel Prize in Physiology or Medicine for his discovery of the bacterium causing tuberculosis.
Although Koch arguably made the greatest theoretical contribution to understanding anthrax, other researchers were more concerned with the practical questions of how to prevent the disease. In Britain, where anthrax affected workers in the wool, worsted, hides, and tanning industries, it was viewed with fear. John Henry Bell, a doctor based in Bradford, first made the link between the mysterious and deadly "woolsorter's disease" and anthrax, showing in 1878 that they were one and the same. In the early 20th century, Friederich Wilhelm Eurich, the German bacteriologist who settled in Bradford with his family as a child, carried out important research for the local Anthrax Investigation Board. Eurich also made valuable contributions to a Home Office Departmental Committee of Inquiry, established in 1913 to address the continuing problem of industrial anthrax. His work in this capacity, much of it collaboration with the factory inspector G. Elmhirst Duckering, led directly to the Anthrax Prevention Act (1919).
Anthrax posed a major economic challenge in France and elsewhere during the 19th century. Horses, cattle, and sheep were particularly vulnerable, and national funds were set aside to investigate the production of a vaccine. Noted French scientist Louis Pasteur was charged with the production of a vaccine, following his successful work in developing methods which helped to protect the important wine and silk industries.
In May 1881, Pasteur – in collaboration with his assistants Jean-Joseph Henri Toussaint, Émile Roux and others – performed a public experiment at Pouilly-le-Fort to demonstrate his concept of vaccination. He prepared two groups of 25 sheep, one goat, and several cattle. The animals of one group were injected with an anthrax vaccine prepared by Pasteur twice, at an interval of 15 days; the control group was left unvaccinated. Thirty days after the first injection, both groups were injected with a culture of live anthrax bacteria. All the animals in the unvaccinated group died, while all of the animals in the vaccinated group survived.
After this apparent triumph, which was widely reported in the local, national, and international press, Pasteur made strenuous efforts to export the vaccine beyond France. He used his celebrity status to establish Pasteur Institutes across Europe and Asia, and his nephew, Adrien Loir, travelled to Australia in 1888 to try to introduce the vaccine to combat anthrax in New South Wales. Ultimately, the vaccine was unsuccessful in the challenging climate of rural Australia, and it was soon superseded by a more robust version developed by local researchers John Gunn and John McGarvie Smith.
The human vaccine for anthrax became available in 1954. This was a cell-free vaccine instead of the live-cell Pasteur-style vaccine used for veterinary purposes. An improved cell-free vaccine became available in 1970.
- The Sterne strain of anthrax, named after the Trieste-born immunologist Max Sterne, is an attenuated strain used as a vaccine, which contains only the anthrax toxin virulence plasmid and not the polyglutamic acid capsule expressing plasmid.
- Strain 836, created by the Soviet bio-weapons program in the 1980s, was later called by the Los Angeles Times "the most virulent and vicious strain of anthrax known to man".
- The virulent Ames strain, which was used in the 2001 anthrax attacks in the United States, has received the most news coverage of any anthrax outbreak. The Ames strain contains two virulence plasmids, which separately encode for a three-protein toxin, called anthrax toxin, and a polyglutamic acid capsule.
- Nonetheless, the Vollum strain, developed but never used as a biological weapon during the Second World War, is much more dangerous. The Vollum (also incorrectly referred to as Vellum) strain was isolated in 1935 from a cow in Oxfordshire. This same strain was used during the Gruinard bioweapons trials. A variation of Vollum, known as "Vollum 1B", was used during the 1960s in the US and UK bioweapon programs. Vollum 1B is widely believed to have been isolated from William A. Boyles, a 46-year-old scientist at the US Army Biological Warfare Laboratories at Camp (later Fort) Detrick, Maryland, who died in 1951 after being accidentally infected with the Vollum strain.
Society and culture
Anthrax spores can survive for very long periods of time in the environment after release. Chemical methods for cleaning anthrax-contaminated sites or materials may use oxidizing agents such as peroxides, ethylene oxide, Sandia Foam, chlorine dioxide (used in the Hart Senate Office Building), peracetic acid, ozone gas, hypochlorous acid, sodium persulfate, and liquid bleach products containing sodium hypochlorite. Nonoxidizing agents shown to be effective for anthrax decontamination include methyl bromide, formaldehyde, and metam sodium. These agents destroy bacterial spores. All of the aforementioned anthrax decontamination technologies have been demonstrated to be effective in laboratory tests conducted by the US EPA or others.
Decontamination techniques for Bacillus anthracis spores are affected by the material with which the spores are associated, environmental factors such as temperature and humidity, and microbiological factors such as the spore species, anthracis strain, and test methods used.
A bleach solution for treating hard surfaces has been approved by the EPA. Chlorine dioxide has emerged as the preferred biocide against anthrax-contaminated sites, having been employed in the treatment of numerous government buildings over the past decade. Its chief drawback is the need for in situ processes to have the reactant on demand.
To speed the process, trace amounts of a nontoxic catalyst composed of iron and tetroamido macrocyclic ligands are combined with sodium carbonate and bicarbonate and converted into a spray. The spray formula is applied to an infested area and is followed by another spray containing tert-butyl hydroperoxide.
Using the catalyst method, a complete destruction of all anthrax spores can be achieved in under 30 minutes. A standard catalyst-free spray destroys fewer than half the spores in the same amount of time.
Cleanups at a Senate Office Building, several contaminated postal facilities, and other US government and private office buildings, a collaborative effort headed by the Environmental Protection Agency showed decontamination to be possible, but time-consuming and costly. Clearing the Senate Office Building of anthrax spores cost $27 million, according to the Government Accountability Office. Cleaning the Brentwood postal facility in Washington cost $130 million and took 26 months. Since then, newer and less costly methods have been developed.
Cleanup of anthrax-contaminated areas on ranches and in the wild is much more problematic. Carcasses may be burned, though often 3 days are needed to burn a large carcass and this is not feasible in areas with little wood. Carcasses may also be buried, though the burying of large animals deeply enough to prevent resurfacing of spores requires much manpower and expensive tools. Carcasses have been soaked in formaldehyde to kill spores, though this has environmental contamination issues. Block burning of vegetation in large areas enclosing an anthrax outbreak has been tried; this, while environmentally destructive, causes healthy animals to move away from an area with carcasses in search of fresh grass. Some wildlife workers have experimented with covering fresh anthrax carcasses with shadecloth and heavy objects. This prevents some scavengers from opening the carcasses, thus allowing the putrefactive bacteria within the carcass to kill the vegetative B. anthracis cells and preventing sporulation. This method also has drawbacks, as scavengers such as hyenas are capable of infiltrating almost any exclosure.
The experimental site at Gruinard Island is said to have been decontaminated with a mixture of formaldehyde and seawater by the Ministry of Defence. It is not clear whether similar treatments had been applied to US test sites.
Anthrax spores have been used as a biological warfare weapon. Its first modern incidence occurred when Nordic rebels, supplied by the German General Staff, used anthrax with unknown results against the Imperial Russian Army in Finland in 1916. Anthrax was first tested as a biological warfare agent by Unit 731 of the Japanese Kwantung Army in Manchuria during the 1930s; some of this testing involved intentional infection of prisoners of war, thousands of whom died. Anthrax, designated at the time as Agent N, was also investigated by the Allies in the 1940s.
A long history of practical bioweapons research exists in this area. For example, in 1942, British bioweapons trials severely contaminated Gruinard Island in Scotland with anthrax spores of the Vollum-14578 strain, making it a no-go area until it was decontaminated in 1990. The Gruinard trials involved testing the effectiveness of a submunition of an "N-bomb" – a biological weapon containing dried anthrax spores. Additionally, five million "cattle cakes" (animal feed pellets impregnated with anthrax spores) were prepared and stored at Porton Down for "Operation Vegetarian" – antilivestock attacks against Germany to be made by the Royal Air Force. The plan was for anthrax-based biological weapons to be dropped on Germany in 1944. However, the edible cattle cakes and the bomb were not used; the cattle cakes were incinerated in late 1945.
Weaponized anthrax was part of the US stockpile prior to 1972, when the United States signed the Biological Weapons Convention. President Nixon ordered the dismantling of US biowarfare programs in 1969 and the destruction of all existing stockpiles of bioweapons. In 1978–79, the Rhodesian government used anthrax against cattle and humans during its campaign against rebels. The Soviet Union created and stored 100 to 200 tons of anthrax spores at Kantubek on Vozrozhdeniya Island; they were abandoned in 1992 and destroyed in 2002.
Sverdlovsk incident (2 April 1979)
Despite signing the 1972 agreement to end bioweapon production, the government of the Soviet Union had an active bioweapons program that included the production of hundreds of tons of anthrax after this period. On 2 April 1979, some of the over one million people living in Sverdlovsk (now called Ekaterinburg, Russia), about 1,370 kilometres (850 mi) east of Moscow, were exposed to an accidental release of anthrax from a biological weapons complex located near there. At least 94 people were infected, of whom at least 68 died. One victim died four days after the release, 10 over an eight-day period at the peak of the deaths, and the last six weeks later. Extensive cleanup, vaccinations, and medical interventions managed to save about 30 of the victims. Extensive cover-ups and destruction of records by the KGB continued from 1979 until Russian President Boris Yeltsin admitted this anthrax accident in 1992. Jeanne Guillemin reported in 1999 that a combined Russian and United States team investigated the accident in 1992.
Nearly all of the night-shift workers of a ceramics plant directly across the street from the biological facility (compound 19) became infected, and most died. Since most were men, some NATO governments suspected the Soviet Union had developed a sex-specific weapon. The government blamed the outbreak on the consumption of anthrax-tainted meat, and ordered the confiscation of all uninspected meat that entered the city. They also ordered all stray dogs to be shot and people not have contact with sick animals. Also, a voluntary evacuation and anthrax vaccination program was established for people from 18–55.
To support the cover-up story, Soviet medical and legal journals published articles about an outbreak in livestock that caused GI anthrax in people having consumed infected meat, and cutaneous anthrax in people having come into contact with the animals. All medical and public health records were confiscated by the KGB. In addition to the medical problems the outbreak caused, it also prompted Western countries to be more suspicious of a covert Soviet bioweapons program and to increase their surveillance of suspected sites. In 1986, the US government was allowed to investigate the incident, and concluded the exposure was from aerosol anthrax from a military weapons facility. In 1992, President Yeltsin admitted he was "absolutely certain" that "rumors" about the Soviet Union violating the 1972 Bioweapons Treaty were true. The Soviet Union, like the US and UK, had agreed to submit information to the UN about their bioweapons programs, but omitted known facilities and never acknowledged their weapons program.
In theory, anthrax spores can be cultivated with minimal special equipment and a first-year collegiate microbiological education. To make large amounts of an aerosol form of anthrax suitable for biological warfare requires extensive practical knowledge, training, and highly advanced equipment.
Concentrated anthrax spores were used for bioterrorism in the 2001 anthrax attacks in the United States, delivered by mailing postal letters containing the spores. The letters were sent to several news media offices and two Democratic senators: Tom Daschle of South Dakota and Patrick Leahy of Vermont. As a result, 22 were infected and five died. Only a few grams of material were used in these attacks and in August 2008, the US Department of Justice announced they believed that Bruce Ivins, a senior biodefense researcher employed by the United States government, was responsible. These events also spawned many anthrax hoaxes.
Due to these events, the US Postal Service installed biohazard detection systems at its major distribution centers to actively scan for anthrax being transported through the mail. As of 2013, no positive alerts by these systems have occurred.
In response to the postal anthrax attacks and hoaxes, the United States Postal Service sterilized some mail using gamma irradiation and treatment with a proprietary enzyme formula supplied by Sipco Industries.
A scientific experiment performed by a high school student, later published in the Journal of Medical Toxicology, suggested a domestic electric iron at its hottest setting (at least 400 °F (204 °C)) used for at least 5 minutes should destroy all anthrax spores in a common postal envelope.
In Aldous Huxley's 1932 dystopian novel Brave New World, anthrax bombs are mentioned as the primary weapon by means of which original modern society is terrorised and in big part eradicated, to be replaced by a dystopian society.
Anthrax attacks have featured in the storylines of various television episodes and films. A Criminal Minds episode follows the attempt to identify an attacker who released anthrax spores in a public park.
Russian researchers estimate arctic permafrost contains around 1.5 million anthrax-infected reindeer carcasses, and the spores may survive in the permafrost for 105 years. A risk exists that global warming in the Arctic can thaw the permafrost, releasing anthrax spores in the carcasses. In 2016, an anthrax outbreak in reindeer was linked to a 75-year-old carcass that defrosted during a heat wave.
- "Symptoms". CDC. 23 July 2014. Archived from the original on 11 May 2016. Retrieved 14 May 2016.
- "Basic Information What is anthrax?". CDC. 1 September 2015. Archived from the original on 17 May 2016. Retrieved 14 May 2016.
- "Who Is at Risk". CDC. 1 September 2015. Archived from the original on 11 May 2016. Retrieved 14 May 2016.
- "Diagnosis". CDC. 1 September 2015. Archived from the original on 11 May 2016. Retrieved 14 May 2016.
- Hendricks, KA; Wright, ME; Shadomy, SV; Bradley, JS; Morrow, MG; Pavia, AT; Rubinstein, E; Holty, JE; Messonnier, NE; Smith, TL; Pesik, N; Treadwell, TA; Bower, WA; Workgroup on Anthrax Clinical, Guidelines (February 2014). "Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults". Emerging Infectious Diseases. 20 (2). doi:10.3201/eid2002.130687. PMC 3901462. PMID 24447897.
- "Treatment". CDC. 14 January 2016. Archived from the original on 11 May 2016. Retrieved 14 May 2016.
- "Anthrax". FDA. 17 June 2015. Archived from the original on 7 May 2016. Retrieved 14 May 2016.
- Anthrax: Global Status. GIDEON Informatics Inc. 2016. p. 12. ISBN 9781498808613. Archived from the original on 10 September 2017.
- "Types of Anthrax". CDC. 21 July 2014. Archived from the original on 11 May 2016. Retrieved 14 May 2016.
- "How People Are Infected". CDC. 1 September 2015. Archived from the original on 26 December 2016. Retrieved 14 May 2016.
- Turnbull, Peter (2008). Anthrax in humans and animals (PDF) (4 ed.). Geneva, Switzerland: World Health Organization. pp. 20, 36. ISBN 9789241547536. Archived (PDF) from the original on 30 November 2016.
- Schlossberg, David (2008). Clinical Infectious Disease. Cambridge University Press. p. 897. ISBN 9781139576659. Archived from the original on 10 September 2017.
- "Anthrax". CDC. National Center for Emerging and Zoonotic Infectious Diseases. 26 August 2009. Archived from the original on 26 December 2016. Retrieved 14 May 2016.
- Cherkasskiy, B. L. (1999). "A national register of historic and contemporary anthrax foci". Journal of Applied Microbiology. 87 (2): 192–195. doi:10.1046/j.1365-2672.1999.00868.x. PMID 10475946.
- "Cutaneous Anthrax". CDC. 21 July 2014. Retrieved 16 February 2018.
- "Anthrax Q & A: Signs and Symptoms". Emergency Preparedness and Response. Centers for Disease Control and Prevention. 2003. Archived from the original on 5 April 2007. Retrieved 19 April 2007.
- Bravata, DM; Holty, JE; Liu, H; McDonald, KM; Olshen, RA; Owens, DK (February 2006). "Systematic review: a century of inhalational anthrax cases from 1900 to 2005". Annals of Internal Medicine. 144 (4): 270–80. doi:10.7326/0003-4819-144-4-200602210-00009. PMID 16490913.
- "Inhalation Anthrax". The New York Times. Archived from the original on 7 August 2017. Retrieved 14 July 2017.
- USAMRIID (2011). USAMRIID's Medical Management of Biological Casualties Handbook (PDF) (7th ed.). US Government Printing Office. ISBN 9780160900150. Archived (PDF) from the original on 9 February 2015.
For the attacks of 2001, CFR was only 45%, while before this time CFRs for IA were >85% (Page 37)
- Kyriacou, DN; Yarnold, PR; Stein, AC; Schmitt, BP; Soltysik, RC; Nelson, RR; Frerichs, RR; Noskin, GA; et al. (February 2007). "Discriminating inhalational anthrax from community-acquired pneumonia using chest radiograph findings and a clinical algorithm". Chest. 131 (2): 489–96. CiteSeerX 10.1.1.691.4935. doi:10.1378/chest.06-1687. PMID 17296652.
- "Gastrointestinal Anthrax". Centers for Disease Control and Prevention. 23 August 2013. Archived from the original on 11 February 2015. Retrieved 10 February 2015.
- Koch, R (1876). "Untersuchungen über Bakterien: V. Die Ätiologie der Milzbrand-Krankheit, begründet auf die Entwicklungsgeschichte des Bacillus anthracis" (PDF). Beitrage zur Biologie der Pflanzen. 2 (2): 277–310. Archived (PDF) from the original on 18 July 2011. [Investigations into bacteria: V. The etiology of anthrax, based on the ontogenesis of Bacillus anthracis], Cohns
- Hongbin Liu; Nicholas H. Bergman; Brendan Thomasan; Shamira Shallom; Alyson Hazen; Joseph Crossno; David A. Rasko; Jacques Ravel; Timothy D. Read; Scott N. Peterson; John Yates III; Philip C. Hanna (1 January 2004). "Formation and Composition of the Bacillus anthracis Endospore". Journal of Bacteriology. 186 (1): 164–178. doi:10.1128/JB.186.1.164-178.2004. PMC 303457. PMID 14679236.
- Pimental, RA; Christensen, KA; Krantz, BA; Collier, RJ (September 2004). "Anthrax toxin complexes: heptameric protective antigen can bind lethal factor and edema factor simultaneously". Biochemical and Biophysical Research Communications. 322 (1): 258–62. doi:10.1016/j.bbrc.2004.07.105. PMID 15313199.
- "Crossrail work stopped after human bones found on site". London Evening Standard. Archived from the original on 2 May 2014.
- Hudson, JA; Daniel, RM; Morgan, HW (2006). "Acidophilic and thermophilic Bacillus strains from geothermally heated antarctic soil". FEMS Microbiology Letters. 60 (3): 279–282. doi:10.1111/j.1574-6968.1989.tb03486.x.
- Guillemin, Jeanne (1999). ANTHRAX, the investigation of a Deadly Outbreak. University of California Press. p. 3. ISBN 978-0-520-22917-4.
- "Anthrax, Then and Now". MedicineNet.com. Archived from the original on 20 May 2008. Retrieved 13 August 2008.
- "Anthrax". Centers for Disease Control. 26 August 2009. Archived from the original on 26 December 2016. Retrieved 26 December 2016.
- "How People Are Infected". Centers for Disease Control. 1 September 2015. Archived from the original on 26 December 2016. Retrieved 26 December 2016.
- "Timeline: How the Anthrax Terror Unfolded". National Public Radio. 15 February 2011. Archived from the original on 26 December 2016. Retrieved 26 December 2016.
- Mu Gao (27 April 2006). "Molecular Basis for Anthrax Intoxication". University of Illinois at Urbana-Champaign. Archived from the original on 26 December 2016. Retrieved 26 December 2016.
- Chvyrkova, I; Zhang, XC; Terzyan, S (August 2007). "Lethal Factor of Anthrax Toxin Binds Monomeric Form of Protective Antigen". Biochemical and Biophysical Research Communications. 360 (3): 690–5. doi:10.1016/j.bbrc.2007.06.124. PMC 1986636. PMID 17617379.
- Levinson, W. (2010). Review of Medical Microbiology and Immunology (11th ed.).
- Forbes, B. A. (2002). Bailey & Scott's Diagnostic Microbiology (11th ed.).
- National Personal Protective Technology Laboratory Respirators Archived 31 July 2017 at the Wayback Machine. National Institute for Occupational Safety and Health. 30 April 2009.
- David V. Cohn (11 February 1996). "Life and Times of Louis Pasteur". School of Dentistry, University of Louisville. Archived from the original on 8 April 2008. Retrieved 13 August 2008.
- Mikesell, P.; Ivins, B. E.; Ristroph, J. D.; Vodkin, M. H.; Dreier, T. M.; Leppla, S. H. (1983). "Plasmids, Pasteur, and Anthrax" (PDF). ASM News. 49: 320–2. Archived from the original (PDF) on 8 August 2017. Retrieved 8 June 2017.
- "Robert Koch (1843–1910)". About.com. Archived from the original on 5 July 2008. Retrieved 13 August 2008.
- Splino M, et al. (2005), "Anthrax vaccines" Archived 2 January 2016 at the Wayback Machine, Annals of Saudi Medicine; 2005 Mar–Apr;25(2):143–9.
- "11 December 2008 Approval Letter". Food and Drug Administration. Archived from the original on 29 June 2017. Retrieved 8 June 2017.
- Esther Schrader (23 December 2003). "Military to Halt Anthrax Shots". Los Angeles Times. Archived from the original on 26 December 2016. Retrieved 26 December 2016.
- "How should I decontaminate during response actions?". Occupational Safety & Health Administration. Archived from the original on 26 December 2016. Retrieved 26 December 2016.
- "CDC Anthrax Q & A: Treatment". Archived from the original on 5 May 2011. Retrieved 4 April 2011.
- "HGSI asks for FDA approval of anthrax drug ABthrax". Forbes. Associated Press. 21 May 2009. Archived from the original on 18 October 2014.
- "FDA approves raxibacumab to treat inhalational anthrax". Archived from the original on 17 December 2012. Retrieved 14 December 2012.
- News Release (21 March 2016). "FDA approves new treatment for inhalation anthrax". FDA.
- Suffin, S.C.; Carnes, W. H.; Kaufmann, A. F. (September 1978). "Inhalation anthrax in a home craftsman". Human Pathology. 9 (5): 594–597. doi:10.1016/S0046-8177(78)80140-3. PMID 101438.
- Schweitzer, Sarah (4 January 2010). "Drummer's anthrax case spurs a public health hunt". The Boston Globe. Archived from the original on 14 December 2013. Retrieved 19 October 2014.
- "PROMED: Anthrax, Human – USA: (New Hampshire)". Promedmail.org. 26 December 2009. Archived from the original on 27 September 2011. Retrieved 17 March 2014.
- "PROMED: Anthrax, Human – USA: (New Hampshire)". Promedmail.org. 18 April 2010. Archived from the original on 27 September 2011. Retrieved 17 March 2014.
- "Man who breathed in anthrax dies". BBC News. 2 November 2008. Archived from the original on 7 March 2016.
- "An Outbreak of Anthrax Among Drug Users in Scotland, December 2009 to December 2010" (PDF). HPS. A report on behalf of the National Anthrax Outbreak Control Team. December 2011. Archived from the original (PDF) on 20 October 2013. Retrieved 14 December 2013.
- McNeil, Donald G. Jr (12 January 2010). "Anthrax: In Scotland, six heroin users die of anthrax poisoning". The New York Times. Archived from the original on 2 January 2016.
- ἄνθραξ. Liddell, Henry George; Scott, Robert; A Greek–English Lexicon at the Perseus Project.
- Harper, Douglas. "anthrax". Online Etymology Dictionary.
- Breniquet, Catherine; Michel, Cécile (31 July 2014). Wool Economy in the Ancient Near East. Oxbow Books. ISBN 9781782976349. Archived from the original on 27 August 2016 – via Google Books.
- de Trevisa, John (1398). Bartholomaeus Anglicus' De Proprietatibus Rerum.
- Stark, James (2013). The Making of Modern Anthrax, 1875–1920: Uniting Local, National and Global Histories of Disease. London: Pickering & Chatto.
- Madigan, M.; Martinko, J., eds. (2005). Brock Biology of Microorganisms (11th ed.). Prentice Hall. ISBN 978-0-13-144329-7.
- M, J (22 September 1906). "John Henry Bell, M.D., M.R.C.S". British Medical Journal. 2 (2386): 735–6. doi:10.1136/bmj.2.2386.735. PMC 2382239.
- "Industrial Infection by Anthrax". British Medical Journal. 2 (2759): 1338. 15 November 1913. PMC 2346352.
- Jones, Susan (2010). Death in a Small Package: A Short History of Anthrax. Baltimore: Johns Hopkins University Press.
- Decker, Janet (2003). Deadly Diseases and Epidemics, Anthrax. Chelesa House Publishers. pp. 27–28. ISBN 978-0-7910-7302-5.
- Geison, Gerald (2014). The Private Science of Louis Pasteur. Princeton University Press.
- Stark, James (2012). "Anthrax and Australia in a Global Context: The International Exchange of Theories and Practices with Britain and France, c.1850–1920". Health and History. 14 (2): 1–25. doi:10.5401/healthhist.14.2.0001.
- "Anthrax and Anthrax Vaccine – Epidemiology and Prevention of Vaccine-Preventable Diseases Archived 24 August 2012 at the Wayback Machine", National Immunization Program, Centers for Disease Control and Prevention, January 2006. (PPT format)
- Willman, David (2007), "Selling the Threat of Bioterrorism", The Los Angeles Times, 1 July 2007.
- Jacobsen, Annie (2015), The Pentagon's Brain: An Uncensored History of DARPA, America's Top Secret Military Research Agency; New York: Little, Brown and Company, pg 293.
- Scott Shane (23 December 2001). "Army harvested victims' blood to boost anthrax". Boston Sun. UCLA Dept. of Epidemiology site. Archived from the original on 29 December 2009. Retrieved 6 August 2009.
- "Sandia decon formulation, best known as an anthrax killer, takes on household mold". 26 April 2007. Archived from the original on 5 September 2008. Retrieved 13 August 2008.
- "The Anthrax Cleanup of Capitol Hill." Documentary by Xin Wang produced by the EPA Alumni Association. Video, Transcript (see p8). May 12, 2015.
- "Remediating Indoor and Outdoor Environments". Archived from the original on 13 October 2013. Retrieved 10 October 2013.
- Wood, Joseph P.; Adrion, Alden Charles (16 April 2019). "Review of Decontamination Techniques for the Inactivation of Bacillus anthracis and Other Spore-Forming Bacteria Associated with Building or Outdoor Materials". Environmental Science & Technology. 53 (8): 4045–4062. Bibcode:2019EnST...53.4045W. doi:10.1021/acs.est.8b05274. ISSN 0013-936X. PMC 6547374. PMID 30901213.
- "Using Bleach to Destroy Anthrax and Other Microbes". Society for Applied Microbiology. Archived from the original on 17 May 2008. Retrieved 13 August 2008.
- Vipin K. Rastogi; Shawn P. Ryan; Lalena Wallace; Lisa S. Smith; Saumil S. Shah; G. Blair Martin (19 March 2010). "Systematic Evaluation of the Efficacy of Chlorine Dioxide in Decontamination of Building Interior Surfaces Contaminated with Anthrax Spores". Applied and Environmental Microbiology. 76 (10): 3343–3351. doi:10.1128/AEM.02668-09. PMC 2869126. PMID 20305025.
- "Pesticide Disposal Goes Green". Science News. Archived from the original on 29 June 2011. Retrieved 8 June 2009.
- "The Anthrax Cleanup of Capitol Hill." Documentary by Xin Wang produced by the EPA Alumni Association. Video, Transcript (see p3). May 12, 2015.
- "The Bulletin Vol. 57 – No. 36, 17 October 2003" (PDF). Archived (PDF) from the original on 2 February 2016. (332 KB)
- William J. Broad (1 March 2002). "Anthrax Expert Faces Fine for Burning Infected Carcasses". The New York Times. Archived from the original on 26 December 2016. Retrieved 26 December 2016.
- "Britain's 'Anthrax Island'". BBC News. 25 July 2001. Archived from the original on 26 December 2016. Retrieved 26 December 2016.
- Bisher, Jamie, "During World War I, Terrorists Schemed to Use Anthrax in the Cause of Finnish Independence", Military History, August 2003, pp. 17–22. Anthrax Sabotage in Finland. Archived 25 October 2009.
- Cole, Leonard A. (1990). Clouds of Secrecy: The Army's Germ Warfare Tests Over Populated Areas. Rowman and Littlefield. ISBN 978-0-8226-3001-2.
- Robertson, David. "Saddam's germ war plot is traced back to one Oxford cow". The Times. Archived from the original on 25 December 2005.
- "UK planned to wipe out Germany with anthrax". Sunday Herald. Glasgow. 14 October 2001.
- Croddy, Eric; Wirtz, James J. (2005). Weapons of mass destruction: an encyclopedia of worldwide policy, technology, and history. ABC-CLIO. p. 21. ISBN 978-1-85109-490-5. Archived from the original on 22 February 2017.
- David Martin (16 November 2001). "Traditional Medical Practitioners Seek International Recognition". Southern African News Features. Archived from the original on 11 May 2013. Retrieved 19 October 2014.
- Guillemin, Jeanne (1999). ANTHRAX, the investigation of a Deadly Outbreak. University of California Press. pp. 275–7. ISBN 978-0-520-22917-4.
- "Plague war: The 1979 anthrax leak". Frontline. PBS. Archived from the original on 17 September 2008. Retrieved 13 August 2008.
- Michael C. Fishbein. "Anthrax – From Russia with Love". Infectious Diseases: Causes, Types, Prevention, Treatment and Facts. MedicineNet.com. Archived from the original on 24 October 2008. Retrieved 13 August 2008.
- Alibek, K. (1999). Biohazard. New York: Delta Publishing. ISBN 978-0-385-33496-9.
- Meselson, M.; Guillemin, J.; Hugh-Jones, M.; Langmuir, A.; Popova, I.; Shelokov, A.; Yampolskaya, O.; et al. (1994). "The Sverdlovsk anthrax outbreak of 1979". Science. 266 (5188): 1202–1208. Bibcode:1994Sci...266.1202M. doi:10.1126/science.7973702. PMID 7973702.
- Sternbach, G. (2002). "The History of Anthrax". Journal of Emergency Medicine. 24 (4): 463–467. doi:10.1016/S0736-4679(03)00079-9. PMID 12745053.
- Josh Barney (17 October 2012). "U.Va. Researchers Find Anthrax Can Grow and Reproduce in Soil". U. Va. Health System. University of Virginia site. Archived from the original on 21 October 2012. Retrieved 1 October 2013.
- "Anthrax as a biological weapon". BBC News. 10 October 2001. Archived from the original on 5 May 2016. Retrieved 16 April 2016.
- Cole, Leonard A. (2009). The Anthrax Letters: A Bioterrorism Expert Investigates the Attacks That Shocked America—Case Closed?. SkyhorsePublishing. ISBN 978-1-60239-715-6. Archived from the original on 3 February 2011.
- Bohn, Kevin (6 August 2008). "U.S. officials declare researcher is anthrax killer". CNN. Archived from the original on 8 August 2008. Retrieved 7 August 2008.
- "Cepheid, Northrop Grumman Enter into Agreement for the Purchase of Anthrax Test Cartridges". Security Products. 16 August 2007. Archived from the original on 16 July 2011. Retrieved 26 March 2009.
- "USPS BDS FAQ" (PDF).
- "Latest Facts Update". USPS. 12 February 2002. Archived from the original on 9 May 2009. Retrieved 13 August 2008.
- "Seventeen-year-old devises anthrax deactivator". NBC News. 23 February 2006. Archived from the original on 7 October 2014.
- "Amplification". Criminal Minds. Season 4. Episode 24. 13 May 2009. CBS.
- "Can Dogs Get Anthrax? Archived 6 April 2012 at the Wayback Machine" Canine Nation, 30 October 2001. Retrieved 17 February 2007.
- Dragon, D. C.; Elkin, B. T.; Nishi, J. S.; Ellsworth, T. R. (August 1999). "A review of anthrax in Canada and implications for research on the disease in northern bison". Journal of Applied Microbiology. 87 (2): 208–213. doi:10.1046/j.1365-2672.1999.00872.x.
- Revich, Boris A.; Podolnaya, Marina A. (2011). "Thawing of permafrost may disturb historic cattle burial grounds in East Siberia". Global Health Action. 4: 8482. doi:10.3402/gha.v4i0.8482. ISSN 1654-9880. PMC 3222928. PMID 22114567.
- "40 now hospitalised after anthrax outbreak in Yamal, more than half are children". Archived from the original on 30 July 2016.
- Luhn, Alec (8 August 2016). "Siberian Child Dies After Climate Change Thaws an Anthrax-Infected Reindeer". Wired. Archived from the original on 17 August 2016. Retrieved 19 August 2016.
|Wikimedia Commons has media related to Anthrax (disease).|